Literature DB >> 26286967

PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection.

Wen Xiao1, Long Feng Jiang2, Xiao Zhao Deng3,4, Dan Yan Zhu5, Jia Ping Pei5, Mao Lei Xu1, Bing Jun Li6, Chang Jun Wang6, Jing Hai Zhang6, Qi Zhang6, Zhen Xian Zhou7, Wei Liang Ding8, Xiao Dong Xu6, Ming Yue1.   

Abstract

Programmed cell death-1/programmed cell death-1 ligand 1 (PD-1/PD-L1) inhibitory signal pathway has been verified to be involved in the establishment of persistent viral infections. Blockade of PD-1/PD-L1 engagement to reinvigorate T cell activity is supposed to be a potential therapeutic scheme. Studies have verified the participation of PD-1/PD-L1 in hepatitis C virus (HCV) core protein-regulated immune response. To determine the roles of PD-1/PD-L1 signal pathway in HCV F protein-induced immunoreaction in chronic HCV infection, variations in T cells were examined. The results showed that PD-1 expression on CD8(+) and CD4(+) T cells was increased with HCV F stimulation in both chronic HCV patients and healthy controls, and could be reduced partly by PD-1/PD-L1 blocking. Additionally, by PD-1/PD-L1 blocking, HCV F-induced inhibition of T cell proliferation and promotion of cellular apoptosis were partly or even totally recovered. Furthermore, levels of both Th1 and Th2 cytokines were elevated in the presence of anti-PD-L1 antibody. All these results indicated that PD-1/PD-L1 signal pathway also participates in HCV F protein-induced immunoregulation. PD-1/PD-L1 blocking plays important roles in the restoration of effective functionality of the impaired T cells in chronic HCV patients.

Entities:  

Keywords:  HCV F protein; Hepatitis C virus (HCV); PD-1/PD-L1; Restoration; T cell exhaustion

Mesh:

Substances:

Year:  2016        PMID: 26286967     DOI: 10.1007/s12026-015-8680-y

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  37 in total

1.  Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation.

Authors:  Bertram Bengsch; Bianca Martin; Robert Thimme
Journal:  J Hepatol       Date:  2014-07-10       Impact factor: 25.083

2.  PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.

Authors:  Jacalyn Rosenblatt; Brett Glotzbecker; Heidi Mills; Baldev Vasir; Dimitrios Tzachanis; James D Levine; Robin M Joyce; Kerry Wellenstein; Whitney Keefe; Michael Schickler; Rinat Rotem-Yehudar; Donald Kufe; David Avigan
Journal:  J Immunother       Date:  2011-06       Impact factor: 4.456

3.  Expression of the alternative reading frame protein of Hepatitis C virus induces cytokines involved in hepatic injuries.

Authors:  Marc Fiorucci; Steeve Boulant; Anne Fournillier; Jean Daniel Abraham; Jean Pierre Lavergne; Glaucia Paranhos-Baccala; Geneviève Inchauspé; Christine Bain
Journal:  J Gen Virol       Date:  2007-04       Impact factor: 3.891

4.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

5.  High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma.

Authors:  G Dalagiorgou; N Vassilaki; P Foka; A Boumlic; A Kakkanas; E Kochlios; S Khalili; E Aslanoglou; S Veletza; G Orfanoudakis; D Vassilopoulos; S J Hadziyannis; J Koskinas; P Mavromara
Journal:  J Gen Virol       Date:  2011-02-09       Impact factor: 3.891

6.  Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion.

Authors:  Shawn D Blackburn; Alison Crawford; Haina Shin; Antonio Polley; Gordon J Freeman; E John Wherry
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

7.  High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome.

Authors:  Victoria Kasprowicz; Julian Schulze Zur Wiesch; Thomas Kuntzen; Brian E Nolan; Steven Longworth; Andrew Berical; Jenna Blum; Cory McMahon; Laura L Reyor; Nahel Elias; William W Kwok; Barbara G McGovern; Gordon Freeman; Raymond T Chung; Paul Klenerman; Lia Lewis-Ximenez; Bruce D Walker; Todd M Allen; Arthur Y Kim; Georg M Lauer
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

8.  Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization.

Authors:  Nobuhiro Nakamoto; David E Kaplan; Jennifer Coleclough; Yun Li; Mary E Valiga; Mary Kaminski; Abraham Shaked; Kim Olthoff; Emma Gostick; David A Price; Gordon J Freeman; E John Wherry; Kyong-Mi Chang
Journal:  Gastroenterology       Date:  2008-02-17       Impact factor: 22.682

9.  Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors.

Authors:  Daniela C Kroy; Donatella Ciuffreda; Jennifer H Cooperrider; Michelle Tomlinson; Garrett D Hauck; Jasneet Aneja; Christoph Berger; David Wolski; Mary Carrington; E John Wherry; Raymond T Chung; Kenneth K Tanabe; Nahel Elias; Gordon J Freeman; Rosemarie H de Kruyff; Joseph Misdraji; Arthur Y Kim; Georg M Lauer
Journal:  Gastroenterology       Date:  2013-10-19       Impact factor: 22.682

Review 10.  The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion.

Authors:  Kimberly A Hofmeyer; Hyungjun Jeon; Xingxing Zang
Journal:  J Biomed Biotechnol       Date:  2011-09-25
View more
  7 in total

Review 1.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

Review 2.  CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?

Authors:  Alexandra M Miggelbrink; Joshua D Jackson; Selena J Lorrey; Ethan S Srinivasan; Jessica Waibl-Polania; Daniel S Wilkinson; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2021-06-14       Impact factor: 12.531

Review 3.  Viral Manipulation of Host Inhibitory Receptor Signaling for Immune Evasion.

Authors:  Eugenia Z Ong; Kuan Rong Chan; Eng Eong Ooi
Journal:  PLoS Pathog       Date:  2016-09-01       Impact factor: 6.823

4.  Human CD8+CD28- T Suppressor Cells Expanded by IL-15 In Vitro Suppress in an Allospecific and Programmed Cell Death Protein 1-Dependent Manner.

Authors:  Fu Feng; Yanjun Liu; Guihuan Liu; Ping Zhu; Manman Zhu; Hua Zhang; Xiao Lu; Jiumin Liu; Xunrong Luo; Yuming Yu
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

5.  HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles.

Authors:  Mohamed Tarek M Shata; Enass A Abdel-Hameed; Susan D Rouster; Li Yu; Meina Liang; Esther Song; Mark T Esser; Norah Shire; Kenneth E Sherman
Journal:  Pathog Immun       Date:  2019-02-13

6.  Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals.

Authors:  Shihui Li; Eishiro Mizukoshi; Kazunori Kawaguchi; Miyabi Miura; Michiko Nishino; Tetsuro Shimakami; Kuniaki Arai; Taro Yamashita; Yoshio Sakai; Tatsuya Yamashita; Masao Honda; Shuichi Kaneko
Journal:  Int J Mol Sci       Date:  2022-10-01       Impact factor: 6.208

7.  PDCD1 and IFNL4 genetic variants and risk of developing hepatitis C virus-related diseases.

Authors:  Valli De Re; Maria Lina Tornesello; Mariangela De Zorzi; Laura Caggiari; Francesca Pezzuto; Patrizia Leone; Vito Racanelli; Gianfranco Lauletta; Stefania Zanussi; Ombretta Repetto; Laura Gragnani; Francesca Maria Rossi; Riccardo Dolcetti; Anna Linda Zignego; Franco M Buonaguro; Agostino Steffan
Journal:  Liver Int       Date:  2021-01       Impact factor: 5.828

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.